NASDAQ:CRNX • US22663K1079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRINETICS PHARMACEUTICALS IN (CRNX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-12 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2026-01-08 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-07 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-09-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-09-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-26 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-02-28 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-02-04 | Wolfe Research | Initiate | Peer Perform |
| 2025-01-22 | Jefferies | Upgrade | Hold -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-14 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.013M -15.34% | 1.039M -74.11% | 7.696M 640.71% | 63.115M 720.10% | 179.67M 184.67% | 426.56M 137.41% | 951.73M 123.12% | 1.626B 70.85% | 2.533B 55.78% | 3.443B 35.93% | 4.723B 37.18% | |
| EBITDA YoY % growth | -221.51M -32.72% | -336.069M -51.72% | -512.879M -52.61% | -510.391M 0.49% | -437.778M 14.23% | -232.53M 46.88% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -222.608M -32.60% | -338.854M -52.22% | -516.769M -52.50% | -552.667M -6.95% | -484.132M 12.40% | -308.48M 36.28% | 90.194M 129.24% | 629.75M 598.22% | 1.367B 117.07% | 2.131B 55.89% | 3.079B 44.49% | |
| Operating Margin | -5,547.17% | -32,613.47% | -6,714.77% | -875.65% | -269.46% | -72.32% | 9.48% | 38.73% | 53.97% | 61.89% | 65.19% | |
| EPS YoY % growth | -3.70 -17.83% | -3.71 -0.27% | -4.94 -33.15% | -5.02 -1.52% | -4.27 14.84% | -2.50 41.44% | 0.03 101.22% | 3.93 12,741.67% | 8.37 113.02% | 12.64 50.97% | 19.88 57.30% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.25 -20.58% | -1.25 -1.89% | -1.26 8.44% | -1.25 3.09% | -1.12 10.80% | -1.05 16.44% | -1.01 20.43% | -0.93 25.65% | -1.10 1.52% | -1.02 2.31% | -0.93 7.17% | -0.39 58.08% |
| Revenue Q2Q % growth | 8.685M 2,305.82% | 12.657M 1,127.64% | 17.283M 11,986.01% | 24.116M 291.43% | 31.042M 257.42% | 42.425M 235.19% | 51.469M 197.80% | 64.692M 168.25% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -109.795M 0.62% | -109.189M 14.18% | -116.108M 16.88% | -113.561M 12.49% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -133.216M -19.58% | -135.427M -4.89% | -137.65M 3.46% | -135.748M -1.56% | -126.563M 4.99% | -123.681M 8.67% | -119.418M 13.25% | -110.606M 18.52% | N/A | N/A | N/A | N/A |
All data in USD
22 analysts have analysed CRNX and the average price target is 85.75 USD. This implies a price increase of 123.72% is expected in the next year compared to the current price of 38.33.
CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2026-05-07, after the market close.
The consensus EPS estimate for the next earnings of CRINETICS PHARMACEUTICALS IN (CRNX) is -1.25 USD and the consensus revenue estimate is 8.69M USD.
The consensus rating for CRINETICS PHARMACEUTICALS IN (CRNX) is 84.5455 / 100 . This indicates that analysts generally have a positive outlook on the stock.